NASDAQ:RVMD

Revolution Medicines Competitors

$42.67

-2.35 (-5.22 %)

(As of 04/9/2021 12:00 AM ET)

Add

Compare

Today's Range

$42.52

Now: $42.67▼

$45.64

50-Day Range

$41.28

MA: $45.83▼

$49.54

52-Week Range

$20.53

Now: $42.67▼

$56.18

Volume645,521 shs

Average Volume573,372 shs

Market Capitalization$3.13 billion

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Revolution Medicines (NASDAQ:RVMD) Vs. QGEN, RGEN, NBIX, CRSP, XLRN, and FATE

Should you be buying RVMD stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Revolution Medicines, including QIAGEN (QGEN), Repligen (RGEN), Neurocrine Biosciences (NBIX), CRISPR Therapeutics (CRSP), Acceleron Pharma (XLRN), and Fate Therapeutics (FATE).

Revolution Medicines vs. QIAGEN Stock

QIAGEN (NYSE:QGEN) and Revolution Medicines (NASDAQ:RVMD) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk.

Institutional and Insider Ownership

43.6% of QIAGEN shares are owned by institutional investors. Comparatively, 85.8% of Revolution Medicines shares are owned by institutional investors. 9.0% of QIAGEN shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings and price targets for QIAGEN and Revolution Medicines, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
QIAGEN	0	5	9	0	2.64
Revolution Medicines	0	0	2	0	3.00

QIAGEN presently has a consensus target price of $60.76, indicating a potential upside of 18.46%. Revolution Medicines has a consensus target price of $51.00, indicating a potential upside of 19.52%. Given Revolution Medicines' stronger consensus rating and higher probable upside, analysts plainly believe Revolution Medicines is more favorable than QIAGEN.

Earnings and Valuation

This table compares QIAGEN and Revolution Medicines' revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
QIAGEN	$1.53 billion	7.66	$-41,460,000.00	$1.43	35.87
Revolution Medicines	$50.04 million	62.57	$-47,660,000.00	N/A	N/A

QIAGEN has higher revenue and earnings than Revolution Medicines.

Profitability

This table compares QIAGEN and Revolution Medicines' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
QIAGEN	11.18%	17.51%	8.44%
Revolution Medicines	-191.17%	-32.25%	-20.55%

Summary

QIAGEN beats Revolution Medicines on 7 of the 11 factors compared between the two stocks.

Revolution Medicines vs. Repligen Stock

Revolution Medicines (NASDAQ:RVMD) and Repligen (NASDAQ:RGEN) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Revolution Medicines and Repligen, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	0	0	2	0	3.00
Repligen	0	0	5	0	3.00

Revolution Medicines currently has a consensus target price of $51.00, suggesting a potential upside of 19.52%. Repligen has a consensus target price of $204.75, suggesting a potential downside of 0.66%. Given Revolution Medicines' higher possible upside, equities analysts plainly believe Revolution Medicines is more favorable than Repligen.

Insider & Institutional Ownership

85.8% of Revolution Medicines shares are held by institutional investors. Comparatively, 84.3% of Repligen shares are held by institutional investors. 1.7% of Repligen shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Revolution Medicines and Repligen's top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	$50.04 million	62.57	$-47,660,000.00	N/A	N/A
Repligen	$270.24 million	41.77	$21.41 million	$1.07	192.62

Repligen has higher revenue and earnings than Revolution Medicines.

Profitability

This table compares Revolution Medicines and Repligen's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	-191.17%	-32.25%	-20.55%
Repligen	13.40%	6.58%	5.00%

Summary

Repligen beats Revolution Medicines on 7 of the 10 factors compared between the two stocks.

Revolution Medicines vs. Neurocrine Biosciences Stock

Revolution Medicines (NASDAQ:RVMD) and Neurocrine Biosciences (NASDAQ:NBIX) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations and institutional ownership.

Profitability

This table compares Revolution Medicines and Neurocrine Biosciences' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	-191.17%	-32.25%	-20.55%
Neurocrine Biosciences	8.96%	18.18%	9.50%

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Revolution Medicines and Neurocrine Biosciences, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	0	0	2	0	3.00
Neurocrine Biosciences	0	8	12	0	2.60

Revolution Medicines presently has a consensus price target of $51.00, indicating a potential upside of 19.52%. Neurocrine Biosciences has a consensus price target of $129.2222, indicating a potential upside of 38.43%. Given Neurocrine Biosciences' higher possible upside, analysts clearly believe Neurocrine Biosciences is more favorable than Revolution Medicines.

Insider & Institutional Ownership

85.8% of Revolution Medicines shares are owned by institutional investors. Comparatively, 95.3% of Neurocrine Biosciences shares are owned by institutional investors. 4.3% of Neurocrine Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Revolution Medicines and Neurocrine Biosciences' gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	$50.04 million	62.57	$-47,660,000.00	N/A	N/A
Neurocrine Biosciences	$788.10 million	11.13	$37.01 million	$0.39	239.36

Neurocrine Biosciences has higher revenue and earnings than Revolution Medicines.

Summary

Neurocrine Biosciences beats Revolution Medicines on 9 of the 11 factors compared between the two stocks.

Revolution Medicines vs. CRISPR Therapeutics Stock

Revolution Medicines (NASDAQ:RVMD) and CRISPR Therapeutics (NASDAQ:CRSP) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, valuation, dividends, analyst recommendations, earnings and institutional ownership.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Revolution Medicines and CRISPR Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	0	0	2	0	3.00
CRISPR Therapeutics	2	4	12	0	2.56

Revolution Medicines presently has a consensus price target of $51.00, suggesting a potential upside of 19.52%. CRISPR Therapeutics has a consensus price target of $158.80, suggesting a potential upside of 37.20%. Given CRISPR Therapeutics' higher possible upside, analysts plainly believe CRISPR Therapeutics is more favorable than Revolution Medicines.

Valuation & Earnings

This table compares Revolution Medicines and CRISPR Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	$50.04 million	62.57	$-47,660,000.00	N/A	N/A
CRISPR Therapeutics	$289.59 million	30.15	$66.86 million	$1.17	98.92

CRISPR Therapeutics has higher revenue and earnings than Revolution Medicines.

Profitability

This table compares Revolution Medicines and CRISPR Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	-191.17%	-32.25%	-20.55%
CRISPR Therapeutics	-273.10%	-20.72%	-18.35%

Institutional and Insider Ownership

85.8% of Revolution Medicines shares are owned by institutional investors. Comparatively, 66.4% of CRISPR Therapeutics shares are owned by institutional investors. 17.1% of CRISPR Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

CRISPR Therapeutics beats Revolution Medicines on 7 of the 11 factors compared between the two stocks.

Revolution Medicines vs. Acceleron Pharma Stock

Acceleron Pharma (NASDAQ:XLRN) and Revolution Medicines (NASDAQ:RVMD) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends and earnings.

Institutional and Insider Ownership

79.8% of Acceleron Pharma shares are held by institutional investors. Comparatively, 85.8% of Revolution Medicines shares are held by institutional investors. 2.5% of Acceleron Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Acceleron Pharma and Revolution Medicines' top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acceleron Pharma	$73.99 million	103.81	$-124,860,000.00	($2.38)	-53.30
Revolution Medicines	$50.04 million	62.57	$-47,660,000.00	N/A	N/A

Revolution Medicines has lower revenue, but higher earnings than Acceleron Pharma.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Acceleron Pharma and Revolution Medicines, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acceleron Pharma	0	3	10	1	2.86
Revolution Medicines	0	0	2	0	3.00

Acceleron Pharma presently has a consensus price target of $148.2143, indicating a potential upside of 16.84%. Revolution Medicines has a consensus price target of $51.00, indicating a potential upside of 19.52%. Given Revolution Medicines' stronger consensus rating and higher probable upside, analysts plainly believe Revolution Medicines is more favorable than Acceleron Pharma.

Profitability

This table compares Acceleron Pharma and Revolution Medicines' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Acceleron Pharma	-157.84%	-31.62%	-28.11%
Revolution Medicines	-191.17%	-32.25%	-20.55%

Summary

Acceleron Pharma beats Revolution Medicines on 7 of the 12 factors compared between the two stocks.

Revolution Medicines vs. Fate Therapeutics Stock

Revolution Medicines (NASDAQ:RVMD) and Fate Therapeutics (NASDAQ:FATE) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, analyst recommendations, risk, profitability and earnings.

Profitability

This table compares Revolution Medicines and Fate Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	-191.17%	-32.25%	-20.55%
Fate Therapeutics	-810.13%	-35.51%	-25.40%

Insider and Institutional Ownership

85.8% of Revolution Medicines shares are held by institutional investors. Comparatively, 99.7% of Fate Therapeutics shares are held by institutional investors. 21.4% of Fate Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Revolution Medicines and Fate Therapeutics' revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	$50.04 million	62.57	$-47,660,000.00	N/A	N/A
Fate Therapeutics	$10.68 million	684.84	$-98,150,000.00	($1.44)	-54.16

Revolution Medicines has higher revenue and earnings than Fate Therapeutics.

Analyst Ratings

This is a breakdown of current ratings and price targets for Revolution Medicines and Fate Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	0	0	2	0	3.00
Fate Therapeutics	0	4	9	0	2.69

Revolution Medicines currently has a consensus target price of $51.00, indicating a potential upside of 19.52%. Fate Therapeutics has a consensus target price of $108.3125, indicating a potential upside of 38.88%. Given Fate Therapeutics' higher possible upside, analysts plainly believe Fate Therapeutics is more favorable than Revolution Medicines.

Summary

Revolution Medicines beats Fate Therapeutics on 6 of the 11 factors compared between the two stocks.